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1640In patients with nonacute coro-
nary artery disease (CAD), the
COURAGE (Clinical Outcomes
Utilizing Revascularization and
Aggressive Drug Evaluation) trial
indicates that up-front percuta-
neous coronary intervention (PCI)
based on angiographic stenosis
severity does not reduce coronary
events more than initial medical
treatment (1). In contrast, ran-
domized trials of PCI report
better outcomes when guided by
fractional ﬂow reserve (FFR) than
when guided by angiographic
severity (2) or when compared to
initial medical treatment (3).However, reduced emergent procedures after FFR-guided
revascularization compared with medical treatment has been
appropriately challenged due to lack of differential deaths or
myocardial infarction (MI) or to interventional bias between
the 2 groups (4).
Several potential explanations have been proposed for these
conﬂicting views. Revascularization procedures may not alter
the natural history of multicentric plaque rupture determined
by complex arterial vascular biology. CAD exists diffusely in
addition to segmental stenosis, so that localized mechanical
intervention may fail to alter long-term disease progression or
outcome. Additionally, anatomic severity on coronary angi-
ography may not reﬂect the physiologic severity that directly
determines ischemia, left ventricular function, and prognosis.
Even more basically, how should we deﬁne ischemia and does
revascularization to relieve ischemia reduce coronary events?
Should we judge “diagnostic” tests primarily by outcomes in
randomized trials using hard endpoints after treatment
decisions based on those tests?
The current ISCHEMIA (International Study of Com-
parative Health Effectiveness with Medical and Invasive
Approaches) trial (NCT01471522) addresses these issues bysearch grants from Bracco, Philips, GE, Spec-
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. Dr. Gropler consults for Molecular Insightusing noninvasive imaging to identify moderate-to-severe
ischemia prior to randomization between initial medical
management versus up-front mechanical revascularization
guided by FFR. The planned FAME-3 (Fractional Flow
Reserve versus Angiography for Multivessel Evaluation-3) trial
will compare FFR-guided PCI to coronary artery bypass
grafting (CABG) in patients with complex coronary disease – a
marriage in concept between FAME and SYNTAX (SYNergy
Between PCI With TAXUS and Cardiac Surgery) trials.
However, these ongoing or planned studies utilize existing
technologies that have signiﬁcant limitations. First, single-
photon emission computed tomography (SPECT) imaging
is limited by attenuation artifact, low depth dependent spatial
resolution, and a lack of quantitative myocardial perfusion.
Second, measuring FFR requires an invasive coronary angio-
gram that is complexly inﬂuenced by the healthcare reim-
bursement system. Finally, many patients show a discordant
hyperemic pressure gradient (low FFR) but adequate coronary
ﬂow capacity above ischemic levels, as reviewed here.
Noninvasive myocardial perfusion imaging by positron
emission tomography (PET) combines high spatial reso-
lution (down to secondary or tertiary coronary branches)
with quantitative measures of rest and stress myocardial
perfusion in absolute units to compute absolute coronary
ﬂow reserve (CFR). These quantitative measures have been
directly correlated with low-ﬂow thresholds causing is-
chemia. Quantitative myocardial perfusion by PET has
an extensive and technically robust literature, with over
250 papers including almost 15,000 subjects in the past
25 years.
Therefore, we review the physiologic basis for PET
perfusion imaging to provide all the essential noninvasive
measures of severity that, when integrated with clinical
judgment, identify patients for whom revascularization
procedures may reduce coronary events. Given the existing
diagnostic power of PET in nonrandomized studies and
its extensive literature, randomized trials of physiologic
PET to guide revascularization are essential to conﬁrm or
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1641and management of CAD, paralleling the COURAGE,
FAME, and ISCHEMIA trials.
Such trials are essential for speciﬁc PET technology as
well as for answering the more basic clinical question: does
revascularization for any level of ischemia reduce coronary
events compared to medical treatment? If so, how low
can ﬂow go (regardless of the tool) before the beneﬁt of
revascularization surpasses the net beneﬁt of medical
treatment minus procedural risk of revascularization? In
essence, outcomes after revascularization deﬁne the utility
of PET, or any other gatekeeper test, for deciding on
revascularization.
Prevalence, Severity, and Risk
Many if not most adults develop some coronary athero-
sclerosis starting at early ages evolving to a spectrum of
severity from asymptomatic to severe angina to acute coro-
nary syndromes or sudden death (5,6,Online Refs. 1–5).
Prevention by risk factor control remains the most effective
way of reducing adverse outcomes through healthy lifestyle
and medications (5,6,Online Ref. 6). With more advanced
or obstructive disease, individual risk increases substantially.
In contrast to the COURAGE trial (1) showing no survival
beneﬁt for such patients when guided by percent diameter
stenosis, physiologic-based revascularization may reduce
adverse events compared with anatomic-based revasculari-
zation (2,3,Online Refs. 7–10). However, these conclusions
have been questioned given that the combined endpoints
were driven by reduction in urgent revascularizations subject
to interventional bias with no difference in MI or death (4).
Limitation of Current Cardiovascular Paradigm
Stress testing monitors evidence of “ischemia” caused by
inadequate coronary blood ﬂow for the stress demand
(5,6,Online Ref. 11) with its associated cardiovascular risk
(Online Refs. 11–17). Coronary angiography then assesses
the anatomic severity as a basis for medical or mechanical
treatment (Online Refs. 16,17). This current anatomy-
based paradigm does not consistently identify patient
groups whose prognosis can be improved by PCI, as
demonstrated in several randomized trials (1,Online
Refs. 18–21). By comparison, patients selected for PCI
guided by FFR may improve prognosis compared to PCI
based on angiographic severity (2,3,Online Refs. 7–10).
These data suggest the possibility of suboptimal patient
selection by anatomic endpoints, rather than a general
ineffectiveness of PCI, albeit only a hypothesis being
addressed by the ISCHEMIA trial (4).
Physiologic stenosis severity by either PET or FFR
compared to the angiogram as the guide to bypass surgery in
a randomized trial has not been reported. However, the
well documented variability of visually estimated percent
diameter stenosis, common prevalence of diffuse disease,
particularly of the reference vessel, multiple stenosis, andheterogeneous remodeling raises a testable hypothesis for
potential physiologically guided coronary bypass surgery in
addition to anatomic detail for surgical decisions.
Why Physiologic Severity of
Coronary Artery Disease?
When integrated with clinical circumstances, regional abso-
lute myocardial perfusion is a fundamental parameter, such
as blood pressure, cardiac output, and blood oxygen content.
In an extensive literature, cardiac PET measures absolute
myocardial perfusion and CFR, as reviewed subsequently.
While coronaryﬂow and stenosis pressure gradient are related,
which of these physiologic measures predominantly causes
ischemia during stress? Are pressure gradient and ﬂow
interchangeable to guide procedures, or is 1 predominantly
more useful for deciding on revascularization or are both
optimal?Physiologic Versus Anatomic Severity
Stenosis ﬂuid dynamics in experimental models. An-
atomic and physiologic measures of stenosis severity have
evolved in parallel over the past 40 years. Stenosis dimen-
sions and their pressure/ﬂow effects have been integrated
into ﬂuid dynamic equations and validated in experimental
models (7–10,Online Refs. 22–31). Based on animal
stenosis models, the concept that a 70% diameter narrowing
identiﬁes “critical stenosis” reducing coronary ﬂow capacity
(7) persists as an anatomic threshold for revascularization.
This ﬁrst experimental observation demonstrated the
concept of coronary ﬂow reserve related and alternative to
anatomic severity but was not reported as diagnostic criteria
for revascularization.
Percent stenosis has a historical record and usefulness as
a measure of stenosis severity, also related to physiologic
effects as reported by the senior author 40 years ago (7–9).
However, the limitations of percent stenosis are also well
established, particularly with documentation of diffuse
disease, disease of the reference artery or segment, multiple
stenosis, heterogeneous remodeling and endothelial dys-
function having complex cumulative effects on coronary
ﬂow and pressure not accounted for by a single percent
diameter narrowing (11–14,Online Refs. 32–34). Evidence
over the intervening years has proven percent diameter
stenosis as an inadequate measure of severity for guiding
management (11–14,Online Refs. 32–34).
There is a pronounced curvilinear correlation between
percent stenosis and CFR for composite data from con-
trolled, idealized experimental stenoses (7–9,Online
Refs. 24,27). However, the variability within and among
different experiments is large for CFR given a speciﬁc
anatomic stenosis severity. Similarly anatomic severity varies
greatly for given a speciﬁc CFR. Therefore, the initial
experimental data proved a concept correlating anatomy
with function in single experimental stenosis of normal
Gould et al. JACC Vol. 62, No. 18, 2013
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1642animal coronary arteries. However, even for these idealized
single experimental stenosis, variation in percent stenosis for
each level of reduced ﬂow reserve remains too large for
individualized clinical application and was not proposed for
guiding management in the original physiologically oriented
paper (7).
Therefore, the basic concepts of FFR, CFR, and their
interplay are fundamental for clinical application of quanti-
tative myocardial perfusion or of FFR for invasive decisions.
Figure 1 shows coronary ﬂow, aortic pressure, and coronary
pressure at rest and at hyperemia (9). As ﬂow increases,
distal coronary pressure falls due to the increased pressure
gradient across a stenosis at elevated ﬂow.
CFR (also called absolute CFR) equals the ratio of
maximum stress ﬂow to rest ﬂow for a given arterial distri-
bution with or without a stenosis or diffuse narrowing (7).
Relative coronary ﬂow reserve (relative CFR) equals the ratio
of maximum stress ﬂow in the diseased artery to maximum
ﬂow in the absence of disease in either the same or adjacent
arterial distribution (8–10,14–16,Online Ref. 27). FFR as
now used clinically equals the ratio of coronary pressure to
aortic pressure at pharmacologically induced maximal coro-
nary ﬂow. For a single discrete stenosis in the absence of
diffuse disease, the FFR pressure ratio also equals relative
CFR by ﬂow or ﬂow velocity measurements (8–10,14–
16,Online Ref. 27).Figure 1 Pressure Flow Tracings, FFR, and CFR
Upper panel shows coronary ﬂow and aortic and coronary pressures without stenosis at r
aortic to coronary pressure gradient with a moderately severe stenosis at rest and during
pressure at maximum stress ﬂow and therefore reﬂects relative ﬂow reserve. Absolute cor
ratio of maximum stress ﬂow with a stenosis to maximum stress ﬂow without a stenosisStenosis ﬂuid dynamics in clinical application. Studies in
humans show poor or no correlation between CFR or
FFR and percent stenosis by anatomic imaging due to
varying degrees of diffuse disease, multiple stenosis and
heterogeneous arterial remodeling (11–14,Online
Refs. 32–34) not present in the animal models.
Pressure-based FFR was derived as a proxy measure of
relative CFR in units of a fraction or decimal of 1.0 (10,15)
as in Figure 1. Flow-based CFR is a direct measure of
coronary ﬂow capacity. Quantitative perfusion imaging
provides absolute perfusion normalized to distal myocardial
mass, its regional distribution, absolute and relative CFR.
Directly measured CFR by intracoronary techniques predicts
coronary events (Online Refs. 8,35), paralleling risk predic-
tion of pressure-derived FFR. Although the 2 physiologic
measures of ﬂow and pressure in the coronary arteries are
related, they are neither synonymous nor redundant (17–20).
For discrete segmental stenosis in small series of patients,
Figure 2 demonstrates that FFR determined invasively
from the pressure ratio equals relative CFR measured by
PET (15,16). This equivalence of FFR and relative CFR
for discrete stenosis was also conﬁrmed experimentally
during the experimental derivation and validation of
FFR (10).
However, ﬂow-based CFR and pressure-based FFR may
not show comparable severity for the same stenosis inest and during coronary vasodilator stress. Lower panel shows coronary ﬂow and the
vasodilator stress. Fractional ﬂow reserve (FFR) is the ratio of coronary to aortic
onary ﬂow reserve (CFR) is the ratio of maximum ﬂow to rest ﬂow. Relative CFR is the
comparable to FFR. Adapted with permission from Lipscomb and Gould (9).
Figure 2 FFR by Intracoronary Pressure Wire and Relative CFR by PET
Fractional ﬂow reserve (FFR) measured by intracoronary pressure wire correlated well with relative coronary ﬂow reserve (RFR) derived from absolute coronary ﬂow reserve (CFR)
measured by positron emission tomography (PET) in these small groups of patients selected for single coronary stenosis without diffuse narrowing to demonstrate the initial
concept of pressure derived relative coronary ﬂow reserve. Panel A was adapted with permission from De Bruyne et al. (15). Panel B was adapted with permission from Marques
et al. (16).
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1643roughly 40% of lesions (17,19). This discordance between
FFR and CFR occurs even with purely invasive intra-
coronary technology using combined pressure-ﬂow velocity
wires, thereby reﬂecting physiology, not methodology (17).
Therefore, the discordance arises not from methodological
differences of noninvasive versus invasive measurements, but
reﬂects basic physiology that provides additional insights
into disease severity of clinical relevance (17).
The discordance between FFR and CFR occurs
commonly in 2 types of CAD seen in a larger study pop-
ulation with wider spectrum of disease than the small initial
studies of Figure 2. In the ﬁrst type of CAD, a stenosis
causes abnormal FFR but maximum absolute ﬂow and CFR
are well above ischemic thresholds due to preserved micro-
vascular function and/or arterial remodeling. In the other
type, diffuse narrowing reduces CFR signiﬁcantly but with
only a minimal fall in segmental pressure gradient or FFR
for any segment of the artery (17–20,Online Ref. 36). In
mixed diffuse and segmental disease common clinically,
noninvasive absolute maximal perfusion and CFR together
deﬁne severity for potential optimal clinical decisions in
these complex cases.
For chronic coronary occlusions where classic quadratic
pressure/ﬂow dynamics do not apply, myocardial steal
during vasodilator stress is an established characteristic of
collateralized myocardium wherein stress perfusion falls
below resting perfusion (21–23,Online Refs. 37–43). Myo-
cardial steal is caused by falling distal perfusion pressure at
the collateral origins caused by high ﬂow in the narrowed
feeding artery supplying the collaterals. With exceptionally
well-developed collaterals, steal may not be present but onlylimited CFR. Rarely, collaterals are so well developed as to
provide coronary ﬂow capacity comparable to the native
arteries with no stress-induced defect.
Are FFR Versus CFR Competitive or
Complimentary?
The randomized COURAGE (1) and FAME trials
(2,3,Online Refs. 7–10) have had a major inﬂuence in
moving revascularization decisions from anatomic to phys-
iologic stenosis severity. The optimal binary cutoffs for
FFR were originally selected based on prior noninvasive
stress testing as indirect clinical indicators of “ischemia”.
The initially published lowest FFR cutoffs for “ischemia”
were around 0.65 for selected single-vessel stenosis (Online
Ref. 10) that migrated upward toward 0.80 for patients
with diffuse or triple vessel disease (2,3). However, FFR is
a pressure-derived relative ﬂow reserve. It is not the same as
the more basic, direct measures of maximum absolute stress
ﬂow or CFR from which it is derived. Therefore, FFR is
not a direct measure of low-ﬂow ischemia, and does not
reﬂect absolute ﬂow or absolute CFR that are the deter-
minants of ischemia (18,19), illustrated experimentally in
Figure 3.
Figure 3 shows that myocardial contraction remains
preserved with stable ﬂow, regardless of low perfusion
pressure with FFR down to 0.43 (24). Therefore, while
pressure and ﬂow are related due to homeostatic and ﬂuid
dynamic interactions, ﬂow is fundamentally more important
than pressure for maintaining myocardial function without
ischemia for clinical ranges of distal coronary pressure.
Figure 3
Contractile Function, Coronary Flow, and
Coronary Pressure
In an experimental model, left ventricular contractile function measured as
percent circumferential shortening remains normal if ﬂow is constant and
adequate despite perfusion pressure lowered to 43% of aortic pressure
(Pd/Pa ¼ FFR ¼ 0.43). FFR ¼ fractional ﬂow reserve; Pd ¼ distal coronary
pressure, Pa ¼ aortic pressure. Adapted from Smalling et al. (24).
Figure 4
FFR-CFR Discordance With Coronary Stenosis or
Diffuse CAD
Coronary pressure as a ratio to aortic pressure is on the vertical axis and coronary
ﬂow as a ratio to maximum ﬂow is on the horizontal axis. In the absence of
disease, normal FFR is 1.0 and CFR is 4.0. With diffuse disease CFR is reduced
but in the absence of localized stenosis FFR is 0.9 indicating no signiﬁcant
segmental pressure gradient. With localized stenosis only and preserved vasodi-
lator capacity, FFR is reduced to 0.65 and CFR is reduced to 2.7, which, however,
remains well above ischemic threshold. Thus, for the same adequate CFR well
above ischemic threshold, FFR may be above or below current 0.8 criteria for PCI.
PET images show corresponding stress perfusion for each of these FFR-CFR
discordances (top: normal perfusion capacity [red] with no coronary artery disease
[CAD]; middle: mildly reduced perfusion capacity with diffuse CAD [yellow,
orange]; bottom: severely reduced perfusion capacity with segmental stenosis in
distribution of a diagonal branch [dark green] and diffuse narrowing [yellow]).
Abbreviations as in Figure 2.
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1644Bridging Invasive FFR and
Quantitative PET Perfusion Imaging
Figure 4 illustrates that mild diffuse disease lowers absolute
CFR from the 4.2 as seen in young volunteers to 2.7
commonly seen in patients with risk factors over 40 years
old (17–19,Online Ref. 44). FFR remains high in the
absence of discrete stenosis despite reduced CFR due to
diffuse disease in this schematic. In contrast, a discrete
stenosis without diffuse or small vessel disease may cause
a pressure gradient that lowers FFR to 0.65 but absolute
CFR is 2.7, well above ischemic levels due to maintained
microvascular function.
The coronary ﬂow maps by PET imaging during phar-
macologic stress show corresponding reduced coronary ﬂow
capacity diffusely or as a discrete regional defect in Figure 4
(18). For a given absolute CFR of 2.7 in this example, FFR
and therefore relative CFR may be normal or low depending
whether diffuse disease or segmental stenosis exists. Thus,
discordance may be due to diffuse CAD that lowers coro-
nary ﬂow capacity quantiﬁed by PET perfusion imaging
without segmental perfusion defects, without corresponding
pressure gradient, and therefore with an FFR over 0.8.
Alternatively, coronary ﬂow capacity may be preserved aboveischemic ﬂow thresholds due to maintained microvascular
function and arterial remodeling despite stenosis causing
a pressure gradient and FFR <0.8.
An extensive literature documents discordance in 40% of
patients between FFR and CFR measured invasively (17).
The discordance between absolute CFR and relative CFR
has also been documented in 1,500 cases by quantitative
PET, exactly paralleling the invasive data. The discordance
in about 20% of patients is due to diffuse CAD that lowers
absolute CFR without reduced relative CFR, FFR, or
a localized pressure gradient. The remaining discordance
in 20% of cases is due to adequate absolute CFR despite
a stenosis causing reduced relative CFR, and reduced FFR
reﬂecting a localized pressure gradient but with adequate
absolute perfusion.
Clinical Implications of Adequate CFR
With Low FFR?
For example, a patient with a CFR of 4.0 normally in the
absence of diffuse CAD may have a stenosis causing an
FFR of 0.8 or a relative CFR of 80%. Reduced relative
CFR to 0.8 or 80% of the absolute CFR of 4.0 leaves an
absolute CFR of 3.2 (0.8$4.0 ¼ 3.2) that does not cause
ischemia (no angina, no electrocardiographic (ECG)
change, no contractile dysfunction, clinically stable). Using
Figure 5
FFR-CFR Discordance Due to Stenosis Plus
Diffuse Disease
FFR press D ¼ relative CFR s absolute ischemic ﬂow. This schematic has the
same coordinates as for Figure 4. Mild diffuse narrowing alone lowers CFR to 2.7
with no segmental pressure gradient (FFR 1.0). Mild diffuse narrowing plus
moderate stenosis lower CFR to 1.7 and FFR to 0.75 that are both at ischemic
levels whereas the same diffuse or segmental narrowing alone would not reduce
CFR or FFR to ischemic levels. In the absence of diffuse narrowing, a severe
segmental stenosis is needed to lower CFR to 1.7 with consequent lower FFR of
0.45. Discordance here is the range of FFR from 0.75 to 0.45 reﬂecting relative
CFR for the same reduced absolute CFR of 1.7 due to different relative severity of
diffuse and/or segmental narrowing. PET images show corresponding stress
perfusion for each of these FFR-CFR discordances (top: diffuse narrowing with
diffusely reduced perfusion capacity [yellow, orange] without localized stenosis;
middle: diffuse narrowing [yellow] plus localized severe stenosis [blue]; bottom:
no diffuse narrowing [red] with severe stenosis [blue]). Abbreviations as in
Figure 2.
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1645relative CFR or FFR of 0.8 as the sole criteria for ischemia
includes about 20% of patients with high or adequate CFR
well above ischemic low ﬂow threshold who may not need
revascularization due to absence of ischemia.
Figure 5 shows the combined effect of mixed diffuse
disease and focal stenosis (17–19). Mild diffuse disease
lowers absolute CFR to 2.7 as in the prior example. The
addition of a moderate discrete stenosis lowers CFR to the
ischemic threshold of 1.7 and relative CFR by PET to 0.63
(1.7/2.7 ¼ 0.63) compared to an FFR of 0.75. Therefore,
patients whose CFR is better preserved outside of the
stenotic territory, for example absolute CFR of 3.8, require
a more severe focal stenosis to lower absolute CFR to the
ischemic threshold of 1.7, for example an FFR of 0.45
(1.7/3.8 ¼ 0.45). Thus, for disease that lowers absolute CFR
to the ischemic threshold, FFR may be 0.65 or 0.45
depending on presence or absence of diffuse disease.What About FAME?
While important studies of clinical outcomes, the FAME I
and II trials (2–4,Online Refs. 7–10) do not link FFR
cutoffs directly to speciﬁc manifestations of ischemia such asstress-induced angina, ECG changes, or contractile
dysfunction at the time of FFR measurement. In the
FAME II trial, approximately 80% of patients with low
FFR 0.80 without initial PCI had no increased myocardial
infarction or death over the group with up-front PCI. The
well documented 40% discordance between coronary ﬂow
reserve and FFR raises an important question about the
FAME II trial data. Would adverse outcomes be reduced
after PCI based on combined FFR-ﬂow data compared with
FFR alone, or compared to medical management aloneda
testable hypothesis of clinical importance?
Predicting Physiology From Anatomy
Beginning with initial experimental coronary artery
stenosis, angiographic dimensions coupled with ﬂuid dy-
namic equations matched observed pressure gradients
and/or CFR on average (7,8,Online Refs. 22–27). The
concept of anatomically based stenosis ﬂow reserve
presaged more recent approaches to predict FFR using
digital subtraction or CT angiogram coupled with
computational ﬂuid dynamics (25,Online Refs. 45–49).
These early and recent anatomic predictions of CFR,
pressure gradient, or FFR show a reasonable average
agreement with experimental observations. However, even
under idealized experimental conditions with a single, well-
deﬁned experimental stenosis, the scatter is large around the
average agreement. This large variability critically limits
predictive certainty for individual cases and remains
currently unacceptable in the threshold ranges of CFR or
FFR used to guide invasive procedures (7,8,25,Online
Refs. 22–27). For example, recently reported diagnostic
accuracy for CT measured FFR was only 73% compared to
directly measured FFR (25).
The variability of anatomically-predicted from directly
measured CFR or FFR arises from several basic reasons: 1)
All anatomic algorithms rely on assumptions derived from
average patient characteristics that, however, commonly do
not match with an individual patient; 2) Spatial resolution
of the noninvasive angiogram, and some invasive angio-
grams, remains inadequate for determining ﬂow and pres-
sure endpoints that depend on the arterial radius raised to
the fourth power; 3) Potential diffuse disease and hetero-
geneous arterial remodeling change arterial dimensions such
that the original normal size of the coronary artery is not
known and cannot be accurately determined from the angio-
gram; 4) Nonanatomic factors such as endothelial dysfunction,
neural-mediated vasomotion, myocardial compression, circu-
lating catecholamines, and ﬂow shear change the relation
of coronary ﬂow to anatomy in profoundly unpredictable
ways; and 5) Collateral circulation cannot be assessed by
anatomically predicted FFR.
Therefore, directly measured ﬂow or pressure remains
essential for individually deﬁning physiologic stenosis
severity as distinct from theoretically predicted severity
derived from anatomy.
Table 1
Graded Absolute Flow and Coronary Flow Reserve Across Spectrum of Disease
(N ¼ 14,962)
Population n
Rest Flow
(cc/min/g)
Stress Flow
(cc/min/g) CFR
Normal controls 3,484 0.82  0.06 2.86  1.29 3.55  1.36
Risk factors only 3,592 0.85  0.08 2.25  1.07 2.80  1.39
Established coronary artery disease 1,650 0.83  0.10 1.71  0.71 2.02  0.70
Mixed (risk factors and/or known coronary artery disease) 4,765 0.97  0.10 1.86  0.58 1.93  0.48
Cardiomyopathy 594 0.73  0.07 1.47  0.56 2.02  0.67
Hypertrophic cardiomyopathy 345 0.90  0.10 1.57  0.33 1.84  0.36
Syndrome X 348 1.06  0.11 2.65  1.31 2.54  1.31
After cardiac transplant 184 1.14  0.18 2.44  1.34 2.29  0.86
N [ 14,962 from 252 unique publications. N-13 ammonia [ 5,541; O-15 water [ 3,161; Rb-82 [ 6,175.
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1646Absolute Myocardial Perfusion by PET
While FFR is an invasive pressure-derived relative CFR,
noninvasive cardiac PET has been proven experimentally
and clinically to measure absolute myocardial perfusion,
absolute and relative CFR. Classic relative uptake PET
images have powerfully advanced clinical imaging, even
without absolute perfusion (22,26–29) due to attenuation
correction, high resolution, and quantitative activity re-
covery. It has the additional advantage of measuring absolute
myocardial perfusion, as proven by a substantial literature
over the past 25 years, highlighted by recent useful reviews
and reports (30–38,Online Refs. 50–81).
Table 1 summarizes the literature on cardiac PET
measuring absolute ﬂow in 14,962 adult patients from
15 countries, spanning nearly 25 years from 250 unique
publications and using 3 different isotopes (itemized for
each paper in the complete table in the Online Appendix)
in addition to numerous hardware and software platforms.
Tables 1 to 4 and Online Tables 1 and 2 show variability
of ﬂow values as expected for the wide prevalence of
subclinical to clinical coronary atherosclerosis, hypertension,
diabetes, endothelial dysfunction and multiple factors
affecting coronary ﬂow, even for “normal healthy volunteers”
in addition to different radionuclides, scanners, imaging
protocols, stress agents, and ﬂow models. Therefore, vari-
ability may be due to biologic variability or due to test–retest
variability (imprecision) of the technology quantiﬁed as
the coefﬁcient of variation, shown in Table 4 for common
measurements made in cardiology.
A systematic approach for interpreting this range of PET
ﬂows has to consider and incorporate the following: 1)
patient composition from manifest CAD to risk factors only
to “normals,” keeping in mind that up to 50% of otherwise
“healthy” volunteers may have unrecognized risk factors
(Online Ref. 44); 2) test–retest variability (imprecision) of
quantitative myocardial perfusion; 3) comparison to the
variability of other common measurements made in cardi-
ology; 4) narrow lower range of ﬂows causing ischemia to
guide procedures because variability at higher ﬂows does not
impact these decisions; 5) each PET facility has to establishits own ﬂow values causing ischemia; and 6) deﬁnition of
“ischemia” has to be comparably deﬁned (some reports
deﬁne “ischemia” as stress-induced angina and signiﬁcant
ECG changes during dipyridamole stress, whereas others
deﬁne ischemia by FFR despite absence of angina or ECG
changes during adenosine stress).
While there is some imprecision in PET ﬂow, the coefﬁ-
cient of variation for normal PET quantitative perfusion
average 14% is within the range for other common cardiac-
related measurements from 10% to 29% such as percent
diameter stenosis by quantitative angiography, ejection frac-
tion by echocardiographic or gated SPECT imaging, SPECT
summed stress scores, serum C-reactive protein, or low-
density lipoprotein levels shown in Table 4.
Moreover, the range of PET ﬂows at the threshold of
ischemia is much narrower than for higher ﬂows seen in
most patients because the variability of ﬂow and CFR in its
upper ranges is not critical for revascularization decisions.
Other imaging technology may become capable of routinely
and accurately measuring quantitative myocardial perfusion
in the future. However, for now, no other tool or method-
ology offers such an extensive track record.
Applying quantitative myocardial perfusion clinically
requires an understanding of its range of values, their associ-
ated effects on the heart, and the speciﬁc therapeutic impli-
cations when integratedwith clinical circumstances. Just as for
FFR or percent stenosis, no test or ﬂow number alone should
be used in isolation for clinical decisions but has to be inte-
grated into and interpreted within the clinical circumstances.
From this clinical decision making viewpoint, myocardial
perfusion falls into 4 broad levels of clinical importance:
normal, reduced but not ischemic, ischemic, or infarcted.
Ranges of Coronary Flow Capacity
and the Ischemic Threshold
Coronary ﬂows can be categorized into ranges for inte-
grating with clinical information. The highest ﬂow is
myocardial perfusion observed in healthy young volunteers
with no risk factors (Online Ref. 44). Intermediate ﬂow is
less than normal volunteers but adequate and above ischemic
Table 2 Ischemic Cutoffs of Absolute Stress Flow and CFR
First Author Citation n Isotope Reference Standard
CFR
(No Units)
Stress Flow
(cc/min/gm)
Cutoff AUC Cutoff AUC
Sambuceti Am J Cardiol 1993;72:990 33 N-13 Dipyridamole ST depression 1.75 0.59 1.15 0.6
Muzik J Am Coll Cardiol 1998;31:534 51 N-13 Clinically normal group and
cath data
2.74 0.91
Nesterov Eur J Nucl Med Mol Imaging
2009;36:1594
48 O-15 Cath %DS >50 (plus FFR in half of cohort) 2.5
Hajjiri J Am Coll Cardiol Img 2009;2:751 27 N-13 Cath %DS 70 2.0 0.86 1.85 0.90
Kajander Circulation 2010;122:603 107 O-15 Cath %DS 50 or FFR0.8 2.5 0.95
Johnson J Am Coll Cardiol Img 2011;4:990 1,674 Rb-82 PET defect, dipyridamole angina/ST 1.74 0.91 0.91 0.98
Morton J Am Coll Cardiol 2012;60:1546 41 N-13 Cath %DS 70 1.44 0.83 1.48 0.69
Fiechter J Nucl Med 2012;53:1230 73 N-13 Cath %DS 50 2.0 0.92
Danad J Nucl Med 2013;54:55 120 O-15 Cath %DS 50 (plus FFR in third of cohort) 2.30 0.81 1.86 0.86
AUC ¼ area under the receiver-operating characteristic curve; CFR ¼ coronary ﬂow reserve; %DS ¼ percent diameter stenosis; FFR ¼ fractional ﬂow reserve; ST ¼ ST depression on ECG.
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1647thresholds. The next lowest category of ﬂow occurs at or
below ischemic thresholds deﬁned as causing angina and/or
ECG changes with segmental stress defects (17–19). The
lowest ﬂow category is in myocardial scar.
Normal and reduced but not ischemic. As summarized in
Table 1, absolute ﬂow and CFR decrease continuously
across the spectrum of CAD, from normal volunteers to risk
factors only to established CAD. Given the wide range of
ﬂows in asymptomatic people, there is no clear threshold for
normal versus abnormal, but instead a graded ﬂow range.
Because most people over 40 years old also have some
degree of coronary atherosclerosis, the average CFR of
2.7  0.9 largely represents effects of diffuse and small
vessel disease. The intermediate level of myocardial perfu-
sion, between normal volunteers and ischemic ﬂows, can be
divided into an upper and lower half reﬂecting degrees of
ﬂow-limiting disease above ischemic levels. These interme-
diate levels above ischemic threshold are rarely associated
with symptoms but reﬂect increasing burden of disease and
adverse risk.
Ischemic threshold. Table 2 summarizes the literature on
absolute ﬂow and CFR by cardiac PET for various deﬁnitions
of ischemia. In the largest report in the literature, maximum
stress ﬂow of 0.91 cc/min/g and absolute CFR of 1.74 best
identiﬁed a group with deﬁnite ischemia (manifest by
a perfusion defect with clinical angina during dipyridamole
stress requiring medication reversal of hyperemia and/or
signiﬁcant ECG changes from baseline) (18,19). TheseTable 3 Prognostic Value of Quantitative Perfusion
First Author Citation n Isotope
Herzog J Am Coll Cardiol 2009;54:150 229 N-13
Ziadi J Am Coll Cardiol 2011;58:740 677 Rb-82
Murthy Circulation 2011;124:2215 2,783 Rb-82
Fukushima J Nucl Med 2011;52:726 275 Rb-82
CI ¼ conﬁdence interval; CPT ¼ cold pressor test.ranges provide the basis for the physiologic threshold of
severity directly related to ischemia that may potentially guide
revascularization procedures when integrated with clinical
judgment and tested in a randomized trial.
Myocardial scar. The lowest ﬂow below ischemic perfusion
reﬂects transmural myocardial scar that typically has resting
ﬂow of 0.2 cc/min/g or less but also typically increases
somewhat with stress ﬂow up to 0.4 cc/min/g and a CFR of
up to 2.0 if the parent artery is patent. This very low absolute
ﬂow with CFR of 2.0 or higher also exempliﬁes why both
measures are needed for understanding any given clinical
circumstance.
Clinically, the most meaningful qualitative reporting of
quantitative ﬂows is either “regionally ischemic” or “reduced
but adequate or without signiﬁcant localized regional stress-
induced perfusion defects.” As reported in the case examples,
the relative images are read out ﬁrst as the primary step
toward a revascularization decision that is modiﬁed to a ﬁnal
recommendation after interpretive integration with the
quantitative ﬂows and clinical circumstances.
Coronary ﬂow map as clinical physiology guide. For the
wide range of conditions seen clinically, both absolute
hyperemic perfusion and CFR together are essential for
deﬁning severity in each highly variable individual. Severe
diffuse disease commonly reduces both endpoints but
without a regional stress-induced perfusion defect or local-
ized pressure gradient. Maximum ﬂow alone may be at the
ischemic level but with low resting ﬂow, as seen with betaFollow-Up Events Adjusted Predictor Hazard Ratio (95% CI)
5.4 yrs 33% CFR <2 1.60 (1.00–2.57)
1.1 yrs 4% CFR <2 2.4 (1.4–4.4)
1.4 yrs 10% CFR tertiles 5.6 (2.5–12.4)
1 yr 15% CFR <2.11 2.93 (1.30–6.65)
Table 4
Test–Retest Variability of Common Cardiovascular
Measurements
Test–Retest Measurement Coefﬁcient of Variation
PET ﬂow cc/min/gm 14%
Angiogram % DS 17%
LDL cholesterol 9.5%
ECHO EF 15%
SPECT EF 17%
SPECT SSS 29%
C-reactive protein 46%
See Online Table 1 for primary source data and references.
DS ¼ diameter stenosis; ECHO ¼ echocardiogram; EF ¼ ejection fraction; LDL ¼ low-density
lipoprotein; PET ¼ positron emission tomography; SSS ¼ summed stress score; SPECT ¼ single-
photon emission computed tomography.
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1648blockade, such that CFR exceeds 2.0 or even 3.0 with no
signs or symptoms of ischemia.
Alternatively, resting ﬂow may be very high due to high
resting pressure-rate product or anxiety thereby reducing
CFR but with adequate or high absolute ﬂow capacity (19).
Rest ﬂows over 1 cc/min/g are commonly due to mildly
elevated heart rate or blood pressure, female gender, medi-
cations (e.g., minoxidil), and/or anxiety or other factors
increasing resting ﬂow demands (Online Ref. 44).
The term “coronary ﬂow capacity” integrates both max-
imum stress ﬂow and CFR because at least 2 of the 3 ﬂow
endpoints (rest ﬂow, stress ﬂow in absolute units, and their
ratio CFR) are needed to deﬁne severity completely as
noted previously (18,19). Figure 6 illustrates a coronary
ﬂow capacity map. Each pixel of the heart map of absolute
CFR and stress ﬂow is plotted on a graph color coded for
the above ranges of ﬂows: high ﬂow of normal volunteers
(red), intermediate ﬂows divided into an upper (orange) and
lower half (yellow), mixed signs of ischemia as either angina
or ECG changes with dipyridamole stress but not both
(green), deﬁnite ischemic threshold or below (blue or purple)
associated with ischemic ﬂow level, or transmural scar
(black). Each color-coded pixel is then mapped back to the
heart image for a distinct regional map of coronary ﬂow
capacity and size overlayed with the typical arterial distri-
butions (Online Ref. 79).
Coronary ﬂow map: clinical application. A substantial,
contiguous area of myocardium with ischemic coronary ﬂow
capacity may indicate invasive revascularization after inte-
gration with clinical circumstances. Small, distal, or
completely global reductions in coronary ﬂow capacity
usually indicate medical therapy due to absence of a focal
epicardial artery stenosis. However, if sizable and associated
with refractory symptoms, intermediate reductions in ﬂow
capacity may merit a coronary angiogram with conﬁrming
FFR as a further guide to intervention as illustrated subse-
quently. Severely reduced coronary ﬂow capacity throughout
the heart with no regional localized defect is nearly always
due to severe diffuse CAD, small vessel disease or failure of
pharmacologic stress. Equally balanced and critical epicardial
stenoses in all vessels that reduce perfusion uniformly toischemic thresholds throughout the heart are clinically rare
(see Online Appendix).
Figure 7 illustrates coronary ﬂow capacity maps in 1 view
for 12 different cases representing the range of diffuse or
localized perfusion defects above and below the ischemic
threshold. Those to the left of the threshold have common
abnormalities that are too mild or too small to warrant
mechanical intervention. Those to the right of the threshold
warrant an angiogram and FFR if clinically indicated.
Relative Uptake PET Perfusion Images
The unique aspects of myocardial perfusion imaging by PET
are attenuation correction, uniform depth independent
resolution, and quantitative activity recovery. Myocardial
distribution of activity is scaled relative to the highest activity
of the left ventricle in units of percent. The good resolution
and attenuation correction provide essential localization,
size, and relative severity of perfusion defects (Online
Ref. 79) as guides for assisting clinical management even
without quantitative perfusion. This sharp visualization
by PET remains important for revascularization decisions
particularly for complex cases after bypass surgery or multiple
stents with recurrent symptoms where the culprit lesion
superimposed on diffuse disease is otherwise unclear.
Figure 8 illustrates detailed localization, size and severity
of multiple complex defects in secondary and tertiary arterial
branches (Online Ref. 80). In this case with remote coronary
bypass surgery, the stress images show small severe defects in
the distribution of the ﬁrst (OM1), second (OM2) obtuse
marginal, and ﬁrst diagonal branches (D1). Diffuse disease
of the left anterior descending is indicated by the longitu-
dinal base-to-apex perfusion gradient. Adequate perfusion in
the ramus intermedius distribution but not at its origin
indicates a patent bypass graft to the ramus intermedius.
Relatively good perfusion in the distribution of the right
coronary artery and the ﬁrst septal perforator rules against
physiologically signiﬁcant ﬂow limiting stenosis of the right
or left main coronary arteries. All these ﬁndings were
conﬁrmed by angiogram.
The ﬁrst step in the decision tree with perfusion imaging
is deﬁning location, size, and severity of defects on the
relative images. As reported over the past 25 years from the
senior author’s clinical cardiac PET consult service (29,39),
relative images with large, severe, defects at 60% to 70% of
maximum activity in a proximal to mid ventricular arterial
distribution involving >10% to 15% of the left ventricle
warrant a coronary angiogram if consistent with clinical
circumstances.
However, because the best or highest relative activity may
have reduced absolute ﬂow capacity due to stenosis or diffuse
disease, the relative images may not show the extent and
severity of diffuse disease or combined diffuse and segmental
disease. Therefore, absolute myocardial perfusion and CFR
are needed for separating effects of segmental and diffuse
disease severity by quantitative ﬂow for comparison to
Figure 6 Coronary Flow Capacity Map in 4 Quadrants With Schematic Overlay of Coronary Arteries
Maximum stress perfusion in cc/min/g and absolute coronary ﬂow reserve (CFR) for each pixel of the cardiac image are plotted on the scatter gram and color coded for the range
of values from normal healthy young volunteers to low ﬂow ischemic threshold values. Each color-coded pixel is projected back to its original location on the cardiac image
thereby producing the 4-quadrant map of coronary ﬂow capacity. This ﬂow capacity map therefore integrates stress perfusion in cc/min/g, CFR and clinically relevant ﬂow
capacity ranges accounting for all resting and stress conditions. The color codes for the upper 4 panel maps and the lower graph are deﬁned in the colored mid-ﬁgure text. These
color codes are the same as for Figures 2, 4, and 5. AV ¼ atrioventricular nodal artery; D ¼ diagonal branch; LAD ¼ left anterior descending artery; LCx ¼ left circumﬂex artery;
LV ¼ left ventricular; OM ¼ obtuse marginal branch; PDA ¼ posterior descending artery; RCA ¼ right coronary artery; RI ¼ ramus intermedius.
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disease.
Commonly, relative images are not normal but show only
small, mild to moderate, distal or scattered stress-induced
perfusion defects that identify coronary atherosclerosis but
do not warrant invasive procedures without other overt
clinical evidence of severe localized epicardial stenosis. Stress
images with only a longitudinal base-to-apex perfusion
gradient indicate mild to moderate diffuse CAD without
segmental stenosis (Online Refs. 72,73,77,81).
Clinical Reports Including Quantitative Perfusion
Potentially, the most widespread powerful clinical applica-
tion of cardiac PET perfusion imaging may be selection ofthe small cohort within the large population of patients with
coronary atherosclerosis who might potentially beneﬁt from
revascularization due to severe ﬂow limiting stenosis, subject
to a randomized trial. Large, severe, regional, stress-induced
perfusion defects on relative uptake images with severe ﬂow
restriction to below ischemic threshold may justify an
angiogram based on high risk associated with large ischemic
areas, again subject to clinical judgment and a randomized
trial of revascularization.
In the Weatherhead PET Center, rest-stress PET
imaging contravenes as unnecessary many invasive proce-
dures that had been recommended before the PET.
Consequently, in nonrandomized cohort analysis, cardiac
PET reduces subsequent or downstream procedures that
lower the overall cost of cardiovascular care (40),
Figure 7
Coronary Flow Maps and Range of Abnormalities in
Coronary Flow Capacity
A map of coronary ﬂow capacity is shown in single view from 12 different patients
with different burden of diffuse or segmental disease and size/severity above or
below the low ﬂow threshold causing ischemia. The size and severity of cases to
the right of the ischemic threshold (max stress perfusion of 0.9 cc/min/g and CFR
of 1.7) indicate potential revascularization as clinically appropriate. Reprinted with
permission from Johnson and Gould (19). Abbreviations as in Figure 6.
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identiﬁes patients whose survival may be improved by
physiologically guided revascularization, subject to
randomized trial. PET may also identify some patients
with unexpected, clinically “silent” disease manifest by
severe large stress defects below ischemic threshold that areFigure 8 Relative Images of Rubidium-82 Uptake in Multivessel Dise
Rest images are in the upper row and stress images in the lower row. See text for detai
Abbreviations as in Figure 6.not identiﬁed by standard clinical evaluation or testing or
associated with clinical symptoms.
An example of unexpected disease severity is illustrated
in the ﬁrst case here. Four other cases are in the Online
Appendix with their PET reports that include a brief
summary, followed by a detailed report including indication,
medical history, procedure, interpretation of relative images,
interpretation of absolute perfusion and CFR, qualitative
coronary calciﬁcation, ventricular function, and ﬁnally a
recommendation for or against invasive procedures inte-
grated with clinical circumstances.
Cases 1 to 5 illustrate the entire spectrum of patients
undergoing PET perfusion imaging for revascularization
decisions. The coronary ﬂow capacity maps speciﬁcally
demonstrate the concept of ischemic ﬂow thresholds for
revascularization decisions. Case 1 (Fig. 9) illustrates large
size and severity of a stress abnormality on relative images and
coronary ﬂow capacity map in a patient with severe stenosis
and diffuse CAD before and after a stent. Case 2 (Online
Fig. 1) shows a large, mild stress abnormality but with
coronary ﬂow capacity well above the ischemic threshold
conﬁrmed by an FFR of 0.85 at a protocol angiogram with no
indication for revascularization. Case 3 (Online Fig. 2) shows
a medium sized, moderately severe, stress abnormality due to
known occlusion of a collateralized ramus branch that,
considered in clinical context, indicated enhanced medical
management without further invasive procedures. Case 4
(Online Fig. 3) shows a small sized, moderately severe stress-
induced relative abnormality that has excellent coronary ﬂow
capacity for which angiography is not indicated. Case 5
(Online Fig. 4) shows minimal localized stress abnormality
but severely diffusely reduced absolute stress ﬂow reﬂectingase
ls of perfusion anatomy. Adapted with permission from Gould et al. (Online Ref. 80).
Figure 9 Case Example and Report
Case 1 illustrates size and severity of a stress abnormality on relative images (A) and coronary ﬂow capacity map (B) in a patient with severe stenosis and diffuse coronary
artery disease (CAD) before (B) and after a stent (C). PET Report for This Case: 66 year-old male with known CAD s/p CABG in 2005 (LIMA-LAD, radial to OM2, SVG-PDA) with
new mild exertional angina. Description: Myocardial perfusion imaging was carried out by positron emission tomography (PET) at resting conditions and during dipyridamole
stress using rubidium-82. Procedure: There were no complications with the procedure. The patient had angina with 2 mm ST-segment depression on EKG after dipyridamole,
resolving after intravenous aminophylline and metoprolol. Baseline blood pressure was 136/78 mm Hg, heart rate 65 beats/min. Findings: Relative Myocardial Perfusion
Images: The PET images show the following (A): 1) A large, severe, anterior, septal, apical, and distal lateral stress-induced defect involving 60% of the left ventricle in the
distribution of the proximal LAD coronary artery; 2) A small size, severe, basal infero-lateral stress induced defect involving 2% of the left ventricle in the distribution of the distal
LCx or LV extension branch of the RCA. Absolute Coronary Flow Reserve & Myocardial Perfusion: For the inferior and mid lateral best perfused areas, absolute myocardial
perfusion (cc/min/gm) was 0.64 at resting conditions, 2.44 after dipyridamole stress, and coronary ﬂow reserve 3.86. In the anterior, septal, and apical regions, rest ﬂow is
similar but stress ﬂow averages 1.0 and coronary ﬂow reserve 1.5, all below ischemic thresholds (B). The proximal septum has a minimum CFR of 0.46 indicating myocardial
steal. Other: 1) The CT scan done for attenuation of PET data shows dense coronary calciﬁcation in all coronary arteries. 2) Gated PET perfusion images showed abnormal left
ventricular contraction with anterior, apical and septal akinesis but normal rubidium trapping at rest indicating viable stunned myocardium of approximately 60% of the LV. The
ejection fraction was 43% at stress with anterior hypokinesis. Conclusions: These ﬁndings suggest high-grade stenosis of the proximal LAD, but patent bypass grafts to the PDA
and OM2 distributions. Based on the PET scan, coronary angiography with a revascularization procedure is essential due to the size and severity of the stress PET abnormalities.
Follow up: At cath, the left main and LAD were stented with subsequent normalization of the threshold map at follow-up (C) with stress ejection fraction of 63%.
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1652severe diffuse CAD without segmental stenosis for which
angiography is not likely useful despite severe diffuse CAD.
Because some physicians may not have in-depth knowl-
edge of coronary physiology, quantitative myocardial perf-
usion, ischemic ﬂow threshold and their clinical relevance,
the cardiology PET consultant has to provide an integrated
technical, physiologic, and clinical interpretation speciﬁc
for each individual. Or the PET reader needs to commu-
nicate with the primary cardiologist the PET ﬁndings in
order to integrate with clinical circumstances for optimal,
tailored management. While other clinical models may work
in different facilities, in the senior author’s cardiac PET
practice, the imaging ﬁndings are integrated with detailed
clinical evaluation so that the PET report provides a clear
recommendation for or against invasive procedures after
integration with clinical circumstances. Invasive cardiologists
at this center speciﬁcally refer patients for and expect this
recommendation to assist their decisions in the cath lab.
Some patients also request a speciﬁc second opinion on
invasive procedures. Without this integrated interpretation,
the unique power of PET for patient management is
partly lost and PET could become “another test” having
very limited impact as reported in the SPARC (Study of
Myocardial Perfusion and Coronary Anatomy Imaging
Roles in Coronary Artery Disease) trial for SPECT (Online
Ref. 83).Additional Uses of PET Perfusion Imaging
Prognosis. A growing body of evidence supports the
prognostic ability of absolute ﬂow when quantiﬁed by
cardiac PET (28,Online Refs. 51–54,71,77). Table 3
summarizes the current literature, showing that intact
CFR is associated with a favorable prognosis. Mechanisti-
cally, a reduced CFR leads to a worse prognosis either
through a severe, focal defect and its future risk of plaque
rupture with an acute coronary syndrome, or through
a global ﬂow reduction that serves as a marker for diffuse
disease and overall CAD burden. Importantly, test related
prognostic risk scores do not account for the effect of treat-
ment on prognosis (Online Ref. 78). Therefore, prognosis
related to all diagnostic imaging becomes somewhat moot
in the absence of a controlled randomized intervention trial.
Endothelial dysfunction. PET may be used to assess
coronary microvascular endothelial dysfunction nonin-
vasively by perfusion imaging with cold pressor stress, or by
resting perfusion heterogeneity that improves with vasodi-
lator stress (Online Refs. 70–78).
Serial imaging. Serial PET perfusion tracks regression or
progression (29,40,41,Online Refs. 85–88). However,
current data suggest that changes in absolute ﬂow or CFR
smaller than about 20% can frequently occur due to
measurement or biological variability (Online Ref. 44).
Therefore, in the absence of signiﬁcant clinical indications,
only large areas of severe worsening by PET are grounds for
considering an angiogram if clinically appropriate.PET changes are often mixed regionally with the greatest
change in areas that were not the worst region at baseline
(29), especially with suboptimal risk factor control. In
a longitudinal study, 77% of changes on follow-up PET
involved areas that were not the most severe defect on the
prior PET, indicating the multicentric or diffuse character of
CAD and its progression or regression (29).
Study limitations. PET technology is complex, not yet
standardized, and the experience from the years of devel-
oping centers not yet encapsulated into widely available
hardware, software algorithms, or protocols for general use,
as reviewed in the Online Appendix. Moreover, the
heterogeneity of clinical practice is associated with substantial
crossovers that complicate randomized trial design and
interpretation. Both of these issues affected the PARR-2
(PET and Recovery Following Revascularization-2) trial
(Online Refs. 89,90) and the ongoing randomized Century
Health Project of the Weatherhead PET Center For Pre-
venting and Reversing Atherosclerosis at the University of
Texas–Houston (Online Ref. 91) (NCT00756379).
Conclusions
In cardiovascular practice, PET perfusion imaging is now
technically advanced enough and demonstrated for potential
broad use to the extent of other current cardiac imaging as
well as reimbursed by Medicare and most third-party
insurers. This review outlines the scientiﬁc basis for clin-
ical cardiac PET to guide management and revascularization
procedures, potentially for optimal outcomes at lower overall
downstream costs as suggested in cohort studies (40) but
remaining to be proven by randomized trials. The current
evidence base now justiﬁes PET perfusion imaging as
a powerful clinical tool to advance current cardiovascular
practice in guiding revascularization decisions.
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For an expanded Methods, Results, and Discussion, references section, and
supplemental ﬁgures and tables, please see the online version of this
article.
